Related Experiment Video
Updated: Apr 11, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma
Yousef Zakharia1, Kais Zakharia, Olivier Rixe
1University of Iowa Division of Hematology/Oncology and Holden Comprehensive Cancer Center , Iowa City, Iowa, USA yousef-zakharia@uiowa.edu.
Introduction:
Based on extensive preclinical data and abundant evidence for clinical activity, vascular endothelial growth factor receptor (VEGFR) inhibitors are currently standard of care for metastatic renal cell carcinoma (mRCC). Axitinib is one of the most selective molecules in the class of anti-angiogenic agents, which confers an optimal profile between its safety and anti-cancer activity spectrum.
Area Covered:
In this review, the authors discuss the different stages that lead to the approval of axitinib in the clinic as well as the current perspectives for its clinical use with other promising therapies in mRCC such as immune checkpoint inhibitors and vaccines.
Expert Opinion:
In 2015, axitinib has emerged as one of the major agents used in mRCC. Based on robust preclinical data, this highly specific VEGFR inhibitor continues to be evaluated in different indications, including the adjuvant setting but also sequential administration with other molecularly targeted agents or combinations with immune therapies.
Insights
Axitinib, a selective vascular endothelial growth factor receptor (VEGFR) inhibitor, is a key treatment for metastatic renal cell carcinoma (mRCC). It shows promise in combination with other therapies, including immune checkpoint inhibitors and vaccines.
Area of Science:
- Oncology
- Pharmacology
Background:
- Vascular endothelial growth factor receptor (VEGFR) inhibitors are standard treatments for metastatic renal cell carcinoma (mRCC).
- Axitinib is a highly selective anti-angiogenic agent with an optimal balance of safety and efficacy.
Purpose of the Study:
- To review the clinical approval process for axitinib in mRCC.
- To discuss current and future clinical applications of axitinib in combination with emerging therapies.
Main Methods:
- Literature review of preclinical and clinical data.
- Analysis of axitinib's role in various treatment settings for mRCC.
Main Results:
- Axitinib has demonstrated significant clinical activity in mRCC.
- The drug is being investigated in adjuvant settings and in combination therapies.
Conclusions:
- Axitinib is a major therapeutic agent for mRCC as of 2015.
- Ongoing research explores axitinib's potential in combination with targeted agents and immunotherapies.
